Recce Pharmaceuticals (ASX:RCE) Net Income From Continuing Operations: A$-14.96 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:RCE Recce Pharmaceuticals Ltd ASX:RCE
18 GF Score
Price A$0.37
! 5 Warning Signs
View Full Analysis

What is Recce Pharmaceuticals Net Income From Continuing Operations?

Recce Pharmaceuticals ASX:RCE +2.78% 18 Net Income From Continuing Operations is A$-14.96 Mil as of Jun. 2026. GuruFocus rates ASX:RCE with a GF Score™ of 18/100. The stock has 5 warning signs investors should review.

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Recce Pharmaceuticals's net income from continuing operations for the six months ended in Jun. 2026 was A$1.60 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2026 was A$-14.96 Mil.

Recce Pharmaceuticals Net Income From Continuing Operations Historical Data

* Premium members only.

The historical data trend for Recce Pharmaceuticals's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Recce Pharmaceuticals Net Income From Continuing Operations Chart

Recce Pharmaceuticals Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.99 -13.08 -17.66 -21.43 -14.96

Recce Pharmaceuticals Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.20 -7.74 -13.69 -16.56 1.60
ASX:RCE
18GF Score
Recce Pharmaceuticals Ltd ASX:RCE
Net Income From Continuing Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Recce Pharmaceuticals Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-14.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income From Continuing Operations of A$-14.96 Mil mean?
Recce Pharmaceuticals (ASX:RCE) has a Net Income From Continuing Operations of A$-14.96 Mil as of Jun. 2026. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Recce Pharmaceuticals and its competitors.
Is Recce Pharmaceuticals' Net Income From Continuing Operations too high?
Recce Pharmaceuticals' current Net Income From Continuing Operations is A$-14.96 Mil. Overall, Recce Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Recce Pharmaceuticals' Net Income From Continuing Operations compare to VRTX and REGN?
Recce Pharmaceuticals' Net Income From Continuing Operations of A$-14.96 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income From Continuing Operations for a Biotechnology company?
A good Net Income From Continuing Operations depends on the Biotechnology industry context. However, Net Income From Continuing Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income From Continuing Operations mean?
A high Net Income From Continuing Operations can signal that a stock is expensive relative to its fundamentals. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Recce Pharmaceuticals and its competitors. Recce Pharmaceuticals's current Net Income From Continuing Operations is A$-14.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recce Pharmaceuticals stock overvalued right now?
Recce Pharmaceuticals (ASX:RCE) has a current Net Income From Continuing Operations of A$-14.96 Mil. The current Net Income From Continuing Operations is A$-14.96 Mil. Recce Pharmaceuticals' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income From Continuing Operations calculated?
Net Income From Continuing Operations is calculated from a company's financial statements. For Recce Pharmaceuticals (ASX:RCE), the current Net Income From Continuing Operations is A$-14.96 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Recce Pharmaceuticals Business Description

Other Exchanges R9Q:Germany
Address 3 Brodie Hall Drive, Suite 10, Technology Park, Bentley, WA, AUS, 6102
Recce Pharmaceuticals Ltd is an Australia-based, globally-focused biotechnology company that is pioneering the development and commercialisation of a drug discovery and development business commercialising new Classes of synthetic anti-infectives with broad-spectrum activity designed to address the urgent health threat of antibiotic-resistant superbugs and emerging viral pathogens. Its patented candidate, RECCE 327, has been developed for the treatment of life-threatening bacterial infections. It has one segment, which is the research and development of pharmaceutical drugs. Geographic segments are Australia, the UK, and the USA, of which the majority of the revenue comes from Australia. It offers antibiotic drugs to treat bacterial infections for Sepsis, Escherichia coli, and Others.
18GF Score

Get the complete analysis for ASX:RCE

Net Income From Continuing Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.37
Price